¿Cómo se diagnostica el hantavirus? PCR, ELISA y qué decirle a tu médico

One of the reasons hantavirus pulmonary syndrome is dangerous is that it looks like influenza in its first days, and the tests that confirm the diagnosis are not part of routine emergency workups. A physician who does not suspect hantavirus will not order the right tests, and by the time the clinical picture becomes unmistakable the patient may already be deteriorating rapidly. This page explains how hantavirus is confirmed, when each test turns positive, what false negatives look like, and how patients can help clinicians reach the correct diagnosis faster.

1. Why routine tests do not diagnose hantavirus

The standard tests ordered in an emergency department for a febrile patient — full blood count, metabolic panel, chest X-ray, blood cultures, flu swab, COVID-19 antigen test, urine analysis — do not detect hantavirus directly. Some of them show abnormalities consistent with hantavirus infection, but none is specific.

The characteristic routine-lab pattern in early HPS includes:

• Thrombocytopenia (falling platelet count, often below 150,000 per microlitre and sometimes well below 100,000)
• Haemoconcentration (elevated haematocrit reflecting capillary leak and fluid shifting out of the intravascular space)
• Left-shifted white cell count with the presence of immunoblasts (atypical lymphocytes) on the peripheral blood smear — a finding that is highly suggestive of HPS when combined with the right clinical context
• Normal or mildly elevated creatinine in HPS (kidney involvement is more prominent in Old World HFRS)
• Elevated lactate dehydrogenase (LDH)
• Bilateral infiltrates on chest X-ray in the cardiopulmonary phase, indistinguishable from ARDS caused by other aetiologies

These findings are non-specific. Thrombocytopenia plus immunoblasts plus bilateral infiltrates in someone with a compatible exposure history should prompt immediate hantavirus testing and ICU-level surveillance, but the pattern alone does not confirm the diagnosis.

2. RT-PCR: the most definitive early test

Reverse-transcription polymerase chain reaction (RT-PCR) detects the RNA of the virus directly in whole blood or serum. It is the most definitive test during the febrile prodromal phase (days 1–7 of illness), when the virus is actively replicating and circulating in the blood.

Key characteristics:

• Timing: Most sensitive during the first four to seven days of illness. Sensitivity falls after the viraemic phase peaks, roughly coinciding with the transition to the cardiopulmonary phase.
• Specimen: EDTA whole blood or serum. Timing of collection relative to illness onset is critical — a sample drawn too early (before the viral load is detectable) or too late (after viraemia has cleared) can produce a negative result in a true case.
• Strain specificity: PCR assays need to be matched to the circulating strain. Reference laboratories maintain strain-specific assay libraries. Assays designed for Sin Nombre virus may not reliably detect Andes virus at the same sensitivity, and vice versa. For the MV Hondius cluster (Andes virus), reference labs in Argentina, Chile, the Netherlands, and the United States have pre-positioned ANDV-specific assays.
• Turnaround time: At a reference laboratory with the correct assay loaded, results are typically available in 12–24 hours. Point-of-care RT-PCR for hantavirus does not exist as a commercial product as of 2026.

3. ELISA serology: IgM and IgG

Enzyme-linked immunosorbent assay (ELISA) detects antibodies produced by the patient's immune system in response to infection, rather than the virus itself. Two immunoglobulin classes matter clinically:

IgM antibodies

IgM is the first class of antibody produced in a new infection. In hantavirus infection, IgM typically becomes detectable at or very shortly after symptom onset — often within the first two days of illness — and remains elevated for weeks to months. This makes IgM ELISA the most practically useful serological test: a positive IgM in a patient presenting with fever and possible exposure is strong evidence of current or very recent infection.

A negative IgM very early on day one or two of symptoms does not exclude infection: the antibody may not yet have reached detectable levels. If clinical suspicion is high and the first IgM is negative, the test should be repeated 24–48 hours later.

IgG antibodies

IgG typically rises after IgM, peaks over one to two weeks, and persists for years — sometimes for life. A single high IgG titre can indicate current infection but can also represent past infection. The most useful pattern is seroconversion: a negative or low IgG on first sampling that becomes positive or rises significantly (four-fold or greater rise) on a sample drawn 10–14 days later. This paired serology approach confirms acute infection when the initial sample is collected too early for IgM to be elevated.

Cross-reactivity issues

Hantavirus IgM and IgG assays can cross-react between strains. A patient exposed to Andes virus may test weakly positive on an assay calibrated for Sin Nombre virus and vice versa. Reference labs confirm species-level diagnosis using more specific techniques such as neutralisation assays. This matters for epidemiological classification but less for clinical management, where the treatment approach (supportive care) is the same regardless of strain.

4. Immunohistochemistry and post-mortem testing

In fatal cases where ante-mortem testing was either not performed or yielded indeterminate results, immunohistochemistry (IHC) on post-mortem lung or kidney tissue can confirm the diagnosis retrospectively. IHC detects viral antigen in tissue sections. This approach has been important in surveillance and in understanding the true burden of hantavirus mortality in retrospective analyses.

5. Who performs these tests and how samples are submitted

Hantavirus testing is not performed at most hospital or commercial laboratories. Samples must be sent to national or regional reference laboratories. In the context of the 2026 MV Hondius outbreak, the following have pre-positioned capacity:

• Argentina: Instituto Nacional de Enfermedades Infecciosas (INEI), ANLIS-Malbrán, Buenos Aires
• Chile: Instituto de Salud Pública (ISP), Santiago
• Netherlands (for European passengers): Erasmus MC / RIVM, Rotterdam and Bilthoven
• United States: CDC Special Pathogens Branch, Atlanta; some state public-health labs with CDC-delegated capacity
• Spain and other EU countries: national reference labs under ECDC network coordination

The treating clinician must notify the public-health authority when ordering hantavirus testing. This triggers both the sample logistics — which involve biosafety handling requirements — and the epidemiological investigation that follows a positive result.

6. The false negative risk and what it means in practice

False negatives in hantavirus testing arise from several sources:

• Timing error: RT-PCR collected after peak viraemia (typically after day 7) may be negative even in a true case. IgM collected on day 1 may be negative simply because antibody has not risen yet.
• Assay-strain mismatch: Using a Sin Nombre assay for an Andes virus patient, or vice versa, can reduce sensitivity.
• Sample handling error: Hantavirus RNA degrades rapidly at room temperature. Samples must be refrigerated or frozen promptly after collection and shipped on dry ice.
• Pre-analytical variation: Haemolysed samples reduce PCR sensitivity.

The clinical implication is that a single negative test in a patient with a strong exposure history and a compatible clinical picture does not exclude hantavirus infection. Management decisions — particularly ICU-level monitoring and early discussion about ECMO availability — should not be deferred solely because the first test came back negative. Repeat testing and consultation with the reference laboratory are appropriate in this scenario.

7. Differential diagnosis: what else it could be

In the early phase, hantavirus HPS is clinically indistinguishable from several other conditions, which is why the exposure history is so important:

8. What to tell your doctor — the exact conversation

The single most effective action a patient can take to accelerate their own diagnosis is to lead with the exposure history, not with symptoms. Symptoms are non-specific; the exposure history is not. Here is the information that changes the differential:

• "I was on the MV Hondius" — give the date of embarkation and disembarkation if you remember them. This single statement will prompt any clinician who has been following the 2026 outbreak to order a hantavirus panel immediately.
• "I was in contact with someone who was on the MV Hondius"— specify whether this was household-level contact, the date of last contact, and whether the contact was confirmed or suspected to have hantavirus.
• "I had rodent contact" — describe the circumstances: cleaning a cabin, disturbing a nest, rodent droppings in a stored vehicle. Give the date.
• "I recently travelled to [region]" — Patagonia, rural Andes, southwestern United States. Specify whether you stayed in rustic accommodation, hiked in backcountry, or spent time in agricultural settings.
• "My symptoms started [date]" — exact date of fever onset helps the laboratory team choose between PCR (best in week one) and serology (best in week two).

If you are not being taken seriously or hantavirus testing is not being ordered despite these disclosures, ask directly: "I would like hantavirus serology and PCR ordered, and I would like the infectious disease team consulted." Patients in most healthcare systems have the right to request specialist consultation.

9. How long does diagnosis take?

From sample collection to result varies by location and infrastructure:

• At an established reference lab with ANDV-specific assays running (Argentina, Chile, Netherlands, U.S. CDC): 12–24 hours for RT-PCR, 4–8 hours for ELISA IgM
• At a national reference lab that needs to ship samples to a specialist centre: 24–72 hours depending on logistics
• At a hospital lab that does not have the assay and must send to a reference lab: 48–96 hours or longer in remote settings

This timeline underlines why clinical management cannot wait for confirmation. A patient with a strong exposure history and a compatible clinical picture should be monitored at ICU level while results are pending. Starting supportive care and securing ECMO availability before deterioration occurs saves lives; waiting for a positive test does not.